Is PMN or CTNM more profitable?

Contineum Therapeutics' return on equity of -27.09% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -237.99% -151.04% Contineum Therapeutics N/A -27.09% -25.64%

Which has preferable earnings and valuation, NVCT or PMN?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is NVCT or PMN more profitable?

Nuvectis Pharma's return on equity of -161.00% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -161.00% -98.88% Promis Neurosciences N/A -237.99% -151.04%

Promis Neurosciences (PMN) Competitors

$12.20 -0.41 (-3.25%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$12.38 +0.18 (+1.48%)

As of 07/24/2026 07:34 PM Eastern

Compare

PMN vs. CTNM, DNA, SLN, AQST, and NVCT

Should you buy Promis Neurosciences stock or one of its competitors? MarketBeat compares Promis Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Promis Neurosciences include Contineum Therapeutics (CTNM), Ginkgo Bioworks (DNA), Silence Therapeutics (SLN), Aquestive Therapeutics (AQST), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry.

How does Promis Neurosciences compare to Contineum Therapeutics?

Promis Neurosciences (NASDAQ:PMN) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Promis Neurosciences has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Contineum Therapeutics' return on equity of -27.09% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Contineum Therapeutics	N/A	-27.09%	-25.64%

Promis Neurosciences has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Contineum Therapeutics	$50M	10.51	-$59.98M	-$1.95	N/A

Promis Neurosciences presently has a consensus price target of $24.00, indicating a potential upside of 96.72%. Contineum Therapeutics has a consensus price target of $20.00, indicating a potential upside of 42.25%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Promis Neurosciences is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Contineum Therapeutics had 4 more articles in the media than Promis Neurosciences. MarketBeat recorded 5 mentions for Contineum Therapeutics and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 1.61 beat Contineum Therapeutics' score of 0.93 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Promis Neurosciences	Very Positive
Contineum Therapeutics	Positive

50.1% of Promis Neurosciences shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Promis Neurosciences and Contineum Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Promis Neurosciences compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ginkgo Bioworks has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market.

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 1 articles in the media. Promis Neurosciences' average media sentiment score of 1.61 beat Ginkgo Bioworks' score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Ginkgo Bioworks	Neutral
Promis Neurosciences	Very Positive

Ginkgo Bioworks presently has a consensus target price of $8.50, indicating a potential upside of 15.47%. Promis Neurosciences has a consensus target price of $24.00, indicating a potential upside of 96.72%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Promis Neurosciences is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Promis Neurosciences has lower revenue, but higher earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$151.40M	3.18	-$312.76M	-$5.36	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Promis Neurosciences has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Promis Neurosciences	N/A	-237.99%	-151.04%

Summary

Promis Neurosciences beats Ginkgo Bioworks on 8 of the 15 factors compared between the two stocks.

How does Promis Neurosciences compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Promis Neurosciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -105.34% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Promis Neurosciences	N/A	-237.99%	-151.04%

Silence Therapeutics currently has a consensus price target of $55.00, indicating a potential upside of 399.09%. Promis Neurosciences has a consensus price target of $24.00, indicating a potential upside of 96.72%. Given Silence Therapeutics' higher probable upside, equities research analysts clearly believe Silence Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Silence Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market.

Promis Neurosciences has lower revenue, but higher earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$839K	620.42	-$88.61M	-$1.59	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

In the previous week, Silence Therapeutics had 3 more articles in the media than Promis Neurosciences. MarketBeat recorded 4 mentions for Silence Therapeutics and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 1.61 beat Silence Therapeutics' score of 0.46 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Promis Neurosciences	Very Positive

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Silence Therapeutics beats Promis Neurosciences on 10 of the 16 factors compared between the two stocks.

How does Promis Neurosciences compare to Aquestive Therapeutics?

Promis Neurosciences (NASDAQ:PMN) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Promis Neurosciences has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Promis Neurosciences currently has a consensus target price of $24.00, indicating a potential upside of 96.72%. Aquestive Therapeutics has a consensus target price of $8.50, indicating a potential upside of 130.98%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aquestive Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Promis Neurosciences has a beta of -0.23, suggesting that its share price is 123% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

Promis Neurosciences has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Aquestive Therapeutics	$44.54M	10.37	-$83.78M	-$0.61	N/A

In the previous week, Aquestive Therapeutics had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for Aquestive Therapeutics and 1 mentions for Promis Neurosciences. Aquestive Therapeutics' average media sentiment score of 1.66 beat Promis Neurosciences' score of 1.61 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Promis Neurosciences	Very Positive
Aquestive Therapeutics	Very Positive

Summary

Aquestive Therapeutics beats Promis Neurosciences on 11 of the 15 factors compared between the two stocks.

How does Promis Neurosciences compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Nuvectis Pharma had 6 more articles in the media than Promis Neurosciences. MarketBeat recorded 7 mentions for Nuvectis Pharma and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 1.61 beat Nuvectis Pharma's score of 0.83 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvectis Pharma	Positive
Promis Neurosciences	Very Positive

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Nuvectis Pharma's return on equity of -161.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Promis Neurosciences	N/A	-237.99%	-151.04%

Nuvectis Pharma has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

Nuvectis Pharma currently has a consensus price target of $35.00, suggesting a potential upside of 81.25%. Promis Neurosciences has a consensus price target of $24.00, suggesting a potential upside of 96.72%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Promis Neurosciences is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Nuvectis Pharma and Promis Neurosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Promis Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMN vs. The Competition

Export

Metric	Promis Neurosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$113.08M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.84	21.11	27.00	23.71
Price / Sales	N/A	164.10	492.66	73.79
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-21.03	7.88	10.28	6.07
Net Income	-$39.72M	$23.81M	$3.60B	$331.84M
7 Day Performance	-19.68%	-3.79%	-1.25%	-1.53%
1 Month Performance	19.02%	-2.59%	-0.35%	-2.46%
1 Year Performance	-50.53%	32.85%	18.41%	13.66%

Promis Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMN Promis Neurosciences	3.7284 of 5 stars	$12.20 -3.3%	$24.00 +96.7%	-46.1%	$113.08M	N/A	N/A	5	Positive News Gap Up
CTNM Contineum Therapeutics	1.6484 of 5 stars	$14.73 +6.0%	$20.00 +35.8%	+146.7%	$519.67M	$50M	N/A	31	News Coverage
DNA Ginkgo Bioworks	1.3127 of 5 stars	$7.86 -0.4%	$8.50 +8.2%	-50.6%	$515.41M	$170.15M	N/A	640
SLN Silence Therapeutics	3.4019 of 5 stars	$11.83 +9.0%	$55.00 +364.9%	+75.5%	$512.50M	$560K	N/A	100
AQST Aquestive Therapeutics	2.3073 of 5 stars	$3.94 -2.5%	$8.50 +115.7%	-12.4%	$506.89M	$44.54M	N/A	160	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMN) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Promis Neurosciences (PMN) Competitors

PMN vs. CTNM, DNA, SLN, AQST, and NVCT

How does Promis Neurosciences compare to Contineum Therapeutics?

Summary

How does Promis Neurosciences compare to Ginkgo Bioworks?

Summary

How does Promis Neurosciences compare to Silence Therapeutics?

Summary

How does Promis Neurosciences compare to Aquestive Therapeutics?

Summary

How does Promis Neurosciences compare to Nuvectis Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Promis Neurosciences (PMN) Competitors

PMN vs. CTNM, DNA, SLN, AQST, and NVCT

How does Promis Neurosciences compare to Contineum Therapeutics?

Which has more volatility and risk, PMN or CTNM?

Is PMN or CTNM more profitable?

Which has stronger earnings and valuation, PMN or CTNM?

Do analysts rate PMN or CTNM?

Does the media favor PMN or CTNM?

Do institutionals and insiders have more ownership in PMN or CTNM?

Summary

How does Promis Neurosciences compare to Ginkgo Bioworks?

Do insiders and institutionals hold more shares of DNA or PMN?

Which has more risk and volatility, DNA or PMN?

Does the media refer more to DNA or PMN?

Do analysts prefer DNA or PMN?

Which has higher valuation & earnings, DNA or PMN?

Is DNA or PMN more profitable?

Summary

How does Promis Neurosciences compare to Silence Therapeutics?

Is SLN or PMN more profitable?

Do analysts prefer SLN or PMN?

Which has more volatility and risk, SLN or PMN?

Which has stronger valuation and earnings, SLN or PMN?

Does the media refer more to SLN or PMN?

Do insiders & institutionals hold more shares of SLN or PMN?

Summary

How does Promis Neurosciences compare to Aquestive Therapeutics?

Is PMN or AQST more profitable?

Do analysts rate PMN or AQST?

Do insiders & institutionals believe in PMN or AQST?

Which has more risk and volatility, PMN or AQST?

Which has better valuation and earnings, PMN or AQST?

Does the media prefer PMN or AQST?

Summary

How does Promis Neurosciences compare to Nuvectis Pharma?

Do institutionals and insiders believe in NVCT or PMN?

Does the media refer more to NVCT or PMN?

Which has preferable earnings and valuation, NVCT or PMN?

Is NVCT or PMN more profitable?

Which has more risk and volatility, NVCT or PMN?

Do analysts recommend NVCT or PMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN vs. The Competition

Promis Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools